Five things for pharma marketers to know: Friday, April 17

Five things for pharma marketers to know: Friday, April 17

The FDA approves generic Copaxone; AstraZeneca's experimental lung-cancer drug demonstrates that it can delay disease progression; PhRMA CEO John Castellani to step down

Bob Finkel launches 'agency alternative'

Bob Finkel launches 'agency alternative'

Kane & Finkel co-founder Bob Finkel launched a healthcare consultancy that will seek out limited-commitment projects.

Amgen motion to delay Neupogen biosimilar denied

Amgen's attempt to delay Zarxio was denied by a US District Court, which said the argument was speculative.

Five things for pharma marketers to know: Thursday, April 16

Five things for pharma marketers to know: Thursday, April 16

FDA approves Amgen heart failure drug; Pfizer halts breast-cancer drug trial over positive results; 30% of study participants asked docs about drug after seeing or reading an ad

FDA committee recommends label change for Onglyza

FDA committee recommends label change for Onglyza

Despite an FDA committee voting that AstraZeneca's diabetes medication carries an acceptable heart risk, analysts say a Merck study will determine the DPP-IV category's fate.

Biogen, PatientsLikeMe use Fitbit to better understand MS

Biogen, PatientsLikeMe use Fitbit to better understand MS

The drugmaker and patient network teamed up to establish a formal framework for deploying activity trackers for patients with MS and for capturing that data.

Novartis leukemia drug ups progression-free survival

Late-stage results show Arzerra patients have a median progression-free survival rate almost double that of chemotherapy-only patients.

Five things for pharma marketers to know: Wednesday, April 15

Five things for pharma marketers to know: Wednesday, April 15

An FDA panel said heart risks should be part of Onglyza's label; the OIG will examine generic price increases; Abbott said its OTC glucose meter will save patients money

J&J reports quarterly boost in drug sales

J&J reports quarterly boost in drug sales

The company reported $7.7 billion in pharma revenue in the first quarter despite a drop in overall sales and profit.

Rockpointe launches new compliance publication

Life Science Compliance Update will address growing compliance concerns in healthcare.

Five things for pharma marketers to know: Tuesday, April 14

Five things for pharma marketers to know: Tuesday, April 14

IBM takes on healthcare data; Mylan settled a lawsuit allowing it to launch generic Viagra by 2017; an FDA committee will meet today to discuss Onglyza

US drug spending shows reliance on specialty Rx

US drug spending shows reliance on specialty Rx

Americans spent 13.1% more on prescription medications in 2014 than they did in 2013, but recent launches indicate competition in the specialty drug space is going to heat up.

Practice Fusion partners with AstraZeneca

Physicians will be notified when patient care is not meeting national guidelines for COPD and asthma.

GSK considering change to sales compensation model

The British drugmaker is reviewing the patient-oriented sales model it introduced in 2011.

Five things for pharma marketers to know: Monday, April 13

Five things for pharma marketers to know: Monday, April 13

Sanofi won't discount new insulin; Takeda appoints new US business head; insurers push back on expensive preventative genetic tests

WebMD to launch app for Apple's smartwatch

WebMD to launch app for Apple's smartwatch

The small screen makes it a user-friendly medication adherence tool.

Five things for pharma marketers to know: Friday, April 10

Five things for pharma marketers to know: Friday, April 10

AstraZeneca diabetes drug may have increased mortality rate; Pfizer accused of knowing about birth defect risks from Zoloft; Eisai to cut 25% of its US workforce

Patients do not feel connected to pharma

Patients do not feel connected to pharma

Wego Health says fixing this problem requires incorporating patient perspectives before and after a product launch.

Pfizer offers grants for PCSK9 research

The drugmaker is calling on researchers to investigate PCSK9s in specific areas of interest.

Doximity to launch Apple Watch app

The app for the smartwatch includes secure encrypted messaging.

Five things for pharma marketers to know: Thursday, April 9

Five things for pharma marketers to know: Thursday, April 9

Novartis reported highest drug sales in 2014; state Medicaid programs spent $1.33 billion on hepatitis-C drugs; former FDA commissioner argues against shortening regulatory review times

FDA Onglyza panel review set for Tuesday

FDA Onglyza panel review set for Tuesday

The panel will focus on heart failure hospitalization rates associated with the diabetes medication.

Mylan plans to acquire OTC and generic drugmaker Perrigo

Generic giant Mylan proposed a deal valued at $30 billion to acquire Perrigo Company.

Pharma tablet presentations falling short

A study said many sales presentations fail to resonate with payer audiences.

Hospira gets fifth FDA warning in two years

The company has received seven warning letters since 2010.

Five things for pharma marketers to know: Wednesday, April 8

Five things for pharma marketers to know: Wednesday, April 8

FDA accepts previously rejected Novo Nordisk insulin application; Merck HCV doublet regimen receives Breakthrough designation for patients with kidney disease; researchers say that rising costs for cancer drugs aren't reasonable

High cancer costs associated with better outcomes

High cancer costs associated with better outcomes

Researchers say countries that spend the most on cancer care have better outcomes, but the explanation behind improved mortality is not clear.

New guidelines recommend wait-and-see strategy for sinus infections

The American Academy of Otolaryngology said taking antibiotics for sinus infections is a slightly better treatment strategy than waiting it out.

FDA open-data platform gains traction

FDA's application programming interfaces, or openFDA, reached 6,000 users less than a year after its launch.

Five things for pharma marketers to know: Tuesday, April 7

Five things for pharma marketers to know: Tuesday, April 7

Merck funds protein-degrading technology; Shire expects approval for a new ADHD medication in 2017; state biosimilar notification laws focus on subtext

Drugmakers weigh more use of digital

Drugmakers weigh more use of digital

The pharma sales model increasingly relies on key account managers rather than sales reps.

Rituxan may have rare-disease use

The cancer and immunology drug may help patients with a condition that affects two people in every one million.

FDA will study the impact prices have on Rx purchases

The study will include DTC and DTP advertising.

Five things for pharma marketers to know: Monday, April 6

Five things for pharma marketers to know: Monday, April 6

Pfizer exec said biosimilar interchangeability definition not happening anytime soon; AARP launches digital health tech studies with Pfizer and UnitedHealthcare; BMS inks gene therapy collaboration deal

Five things for pharma marketers to know: Friday, April 3

Five things for pharma marketers to know: Friday, April 3

Hedge fund activist challenges Shire patents; CMS issues documents on biosimilars; Astellas Pharma and the University of Texas MD Anderson Cancer Center partner on leukemia treatment

CDC examines how US treats ADHD in children

The government agency found that more children are treated with medication than behavioral therapy.

Walgreen Co. sues Endo over pay-for-delay

Walgreen alleges Endo conspired to keep generic Opana ER off the market.

Five things for pharma marketers to know: Thursday, April 2

Five things for pharma marketers to know: Thursday, April 2

Celltrion expects its Remicade biosimilar to hit the US this year; Vivus cuts its sales force; BMJ accuses Novartis of interfering with clinical trials

Teva concealed kickbacks in speaker program, former reps allege

Teva concealed kickbacks in speaker program, former reps allege

Two former Teva sales representatives claim the drugmaker used speaker programs to hide kickbacks for prescribing drugs Copaxone and Azilect.

Johnson & Johnson, GSK settle dispute over OTC advertising claims

Johnson & Johnson, GSK settle dispute over OTC advertising claims

Johnson & Johnson alleged that misleading advertising threatened the $13.2 million in average weekly sales it makes during prime allergy sales season.

Japan seeks more OTC medications

The government is asking consumers which ones they prefer.

FDA finalizes opioid guidance

Opioids lacking abuse-foiling technology will remain available.

Five things for pharma marketers to know: Wednesday, April 1

Five things for pharma marketers to know: Wednesday, April 1

Takeda proposes $2.2-billion settlement to resolve Actos suits; Public Citizen says diabetes drugs are unlawfully promoted; PAIN study says 20% to 30% of opioid drugs are misused

Merck will evaluate Keytruda cancer combo therapy

Merck will collaborate with Syndax to evaluate the pairing of an anti-PD-1 therapy in Keytruda with HDAC inhibitor entinostat.

Bayer expands MIT/Harvard collaboration

The focus will now include cardiovascular disease.

Five things for pharma marketers to know: Tuesday, March 31

Five things for pharma marketers to know: Tuesday, March 31

Pfizer spent over $1 billion on ads last year; Monday's M&A activity accounted for about 25% of this year's total; Actavis is selling its Australian generics business

Teva will acquire Auspex to fill Copaxone patent hole

Teva will acquire Auspex to fill Copaxone patent hole

The drugmaker known for its massive presence in generics purchased Auspex Pharmaceuticals to bolster its growing specialty business.

Horizon makes $1.1-billion rare-disease push

Horizon makes $1.1-billion rare-disease push

Horizon Pharma's purchase of Hyperion Therapeutics will add two rare-disease drugs to its portfolio.

White House "superbug" plan has five-year goal

The White House's National Action Plan for Reducing Antibiotic-Resistant Bacteria proposal includes $1.2 billion in funding to reduce superbug infections and develop new diagnostics.

Medicare shelled out more than $4.7 billion on hep C last year

Key contributors to the total: Sovaldi, Harvoni and Olysio

Five things for pharma marketers to know: Monday, March 30

Five things for pharma marketers to know: Monday, March 30

UnitedHealth Group buys PBM Catamaran; Sanofi launches Toujeo; Teva acquires Auspex Pharmaceuticals

Five things for pharma marketers to know: Friday, March 27

Five things for pharma marketers to know: Friday, March 27

Novo announces it will resubmit Tresiba to the FDA; WHO urges Europe to share cost-effectiveness data; J&J and Google partner to develop robotic surgery system

Diabetes diagnoses jumped as a result of healthcare reform

Diabetes diagnoses jumped as a result of healthcare reform

Diagnoses spiked in states with expanded Medicaid programs. This may mean higher prescription rates, but research shows a lack of diagnoses also has a price.

Shire and Cincinnati Children's Hospital team up in rare diseases

Shire and Cincinnati Children's Hospital team up in rare diseases

The duo hope to begin testing a new treatment within three years.

Researchers say testosterone ads amount to disease mongering

An editorial says the industry's use of terms like "low T" and "andropause" are false and misleading.

Five things for pharma marketers to know: Thursday, March 26

Five things for pharma marketers to know: Thursday, March 26

Regeneron's Eylea won its fourth indication; Sun Pharma wants to revive trust in its products; confidentiality agreements keep Amgen from telling patients their cancer risk

Physicians call for emphasis on women's health research and care

Physicians call for emphasis on women's health research and care

Panelists at a healthcare innovation conference said clinical research and local physician practices need to do more for women's health.

Bristol-Myers Squibb licenses autoimmune program from Novo Nordisk

The drugmaker inks deal with Novo Nordisk to access its biologic discovery research platform.

Five things for pharma marketers to know: Wednesday, March 25

Five things for pharma marketers to know: Wednesday, March 25

Keytruda trial stopped due to positive results; new bill proposes continuing FDA rare pediatric voucher program; AstraZeneca signs five-year research pact with Harvard Stem Cell Institute

Lawmakers propose allowing pharma companies to share some off-label information

Lawmakers propose allowing pharma companies to share some off-label information

The proposal is part of the 21st Century Cures initiative and would permit drugmakers to provide information about "scientific and medical developments" when communicating with providers and payers.

Doctors want specifics on biosimilar labels

An Alliance for Safe Biologic Medicines survey shows what doctors mean by biosimilar transparency.

Five things for pharma marketers to know: Tuesday, March 24

Five things for pharma marketers to know: Tuesday, March 24

Angelina Jolie Pitt discloses she had her fallopian tubes and ovaries removed; the FDA's Zyprexa investigation was inconclusive; Takeda and ImmunoGen sign a $20-million deal

Everyday Health buys rare-disease agency Cambridge BioMarketing

Everyday Health buys rare-disease agency Cambridge BioMarketing

The $38-million deal expands the reach of rare-disease campaigns.

Pharma DTC spending jumps almost 21% in 2014

Pharma DTC spending jumps almost 21% in 2014

Nielsen data shows pharma spent $4.5 billion on DTC ads last year.

Opioid deterrence may work, labeling rules are coming

Opioid deterrence may work, labeling rules are coming

A painkiller manufacturer said abuse-resistant formula lessens abuse, just as the FDA comes under pressure to finalize labeling guidance.

Harrison and Star names co-president

Mario Muredda and Mardene Miller will serve as co-presidents at the healthcare marketing agency.

Baby boomers are no healthier than others

A study shows that greater access to healthcare and lower smoking rates have not made baby boomers healthier than their parents.

Five things for pharma marketers to know: Monday, March 23

Five things for pharma marketers to know: Monday, March 23

Eleven new drugs with blockbuster potential are expected to launch this year; a bill would require FDA to quickly review drugs approved in the EU; Biogen reinforces its focus on hard-to-treat diseases

Five things for pharma marketers to know: Friday, March 20

Five things for pharma marketers to know: Friday, March 20

A judge rules against Amgen in Neupogen case; FDA advisory panel recommends Breio Ellipta for adults with asthma; AstraZeneca partners with Daiichi Sankyo to sell Movantik

ASCO wants to talk value when talking cancer

ASCO wants to talk value when talking cancer

An American Society of Clinical Oncology report shows the organization wants healthcare professionals to think in terms of value.

Sanofi R&D lead takes aim at global drug regulations

The Paris-based drugmaker's global president of R&D said that jumping through different and inconsistent regulatory hoops puts an "enormous" cost on drugmakers.

University develops program to turn social media into adverse drug reaction data

A group of computer science and engineering students at the Carlos III Universidad in Madrid used natural language processing techniques to translate social-media and forum posts into adverse drug reaction data.

Five things for pharma marketers to know: Thursday, March 19

Five things for pharma marketers to know: Thursday, March 19

A Florida Congressman introduced a bill that would expand patent protections; Novo Nordisk expects to increase diabetes medication prices; AbbVie expanded its Alzheimer's research

US pharma market value projected to be $550 billion in five years

US pharma market value projected to be $550 billion in five years

Oncology and diabetes medications are expected to be major areas of growth.

Medtronic teams up with Glooko

The diabetes device manufacturer will soon work with Glooko's platform.

Pfizer takes issue with Little Remedies

The drugmaker, which markets the Dimetapp cough and cold line, sent a complaint to the Better Business Bureaus.

Five things for pharma marketers to know: Wednesday, March 18

Five things for pharma marketers to know: Wednesday, March 18

GlaxoSmithKline respiratory drug's safety profile will be evaluated by FDA advisory panel; Actavis axes 400 New York jobs; physician testifies that he falsified Diovan clinical trial data

23andMe will harness genetic research in new drug discovery unit

23andMe will harness genetic research in new drug discovery unit

The personal genetics company created a therapeutics group to extricate new drug targets from its research database.

Obesity medications still a hard sell

Increased FDA scrutiny has not garnered trust for the new medications.

Five things for pharma marketers to know: Tuesday, March 17

Five things for pharma marketers to know: Tuesday, March 17

Interim results show cancer drug Imbruvica works well with other treatments; two studies show pricey new HCV medications are cost effective; the American College of Physicians wants less cardiac testing

PCSK9 drugs show viability, tolerability

PCSK9 drugs show viability, tolerability

Amgen and Sanofi/Regeneron shared clinical trial data that shows PCSK9 inhibitors dropped LDL levels by around 60%.

FDA approves Boston Scientific atrial fibrillation device

The approval follows three advisory panel reviews and a complete response letter.

Five things for pharma marketers to know: Monday, March 16

Five things for pharma marketers to know: Monday, March 16

New data suggest Amgen's PCSK9 may reduce risks of heart attacks, Salix bidding is war too rich for Endo's blood, Actavis bipolar drug use is expanded to 10- to 17-year-olds.

Five things for pharma marketers to know: Friday, March 13

Five things for pharma marketers to know: Friday, March 13

J&J sues GlaxoSmithKline over Flonase ads, CDC report finds patients with invasive cancer are living for five years or longer have diagnosis, and Bristol-Myers Squibb resubmits its HCV treatment.

Biosimilar uptake will require companies to tell a trustworthy backstory

Biosimilar uptake will require companies to tell a trustworthy backstory

Reactions to the first biosimilar approval show that marketing and education will be essential for the new category to take market share.

Data on investigational cholesterol-lowering meds to be presented at cardiology meeting

The research will be released as pharmacy benefit managers raise concerns about the potential costs of PCSK9 inhibitors.

CVS exec: biosimilars could discount expensive meds by 40% to 50%

The CMO of CVS Health said biosimilars could drive down prices 10% to 20% lower than current investor expectations.

Five things for pharma marketers to know: Thursday, March 12

Five things for pharma marketers to know: Thursday, March 12

The SEC said some company drug prices can be made public, 23andMe launched an R&D division, and Public Citizen is asking the FDA to withdraw a proposal it says will undermine drug safety information.

Endo makes better offer for Salix

Endo makes better offer for Salix

The company argues its offer for Salix is superior to the terms offered by serial acquirer Valeant.

Open Payments glitches limit submissions

Open Payments glitches limit submissions

The CMS said the issues should be resolved this week and will not affect this month's deadline for companies to submit payment data from 2014.

Top insurance lobby backs New York AG in Actavis antitrust case

America's Health Insurance Plans offered its opinion of the Actavis Namenda IR antitrust case, giving its support to New York Attorney General Eric Schneiderman.

AstraZeneca, Joslin Diabetes Center ink three-year collaboration

The partners will focus on developing treatments for metabolic disorders.

Five things for pharma marketers to know: Wednesday, March 11

Five things for pharma marketers to know: Wednesday, March 11

Zogenix spins off painkiller business; Biogen Idec investigates the use of wearables in MS patients; J&J sues Celltrion and Hospira to delay Remicade biosimilar.

Report: US drug spending jumped 13% in 2014

Report: US drug spending jumped 13% in 2014

PBM Express Scripts said last year's trends reflect a major shift in how the pharmaceutical industry does business and that generics are not the bargain they once were.

FDA letter focuses on UCLA claims about an unapproved diagnostic

The agency's Office of Prescription Drug Promotion said a website indicated safety and effectiveness of a diagnostic tool that has not been approved by the FDA.

Collaboration forms to fight misinformation in genetic testing

A recent analysis found that most websites touting personal cancer medicine failed to provide risk data, while an insurer and a health system team up to develop best practices to improve the "how" of genetic testing.

Survey suggests doctors increasingly look for digital engagement

A new survey from Cegedim Relationship Management claims that digital tools are being underutilized and represent an opportunity to meet the demands of HCPs.

The 2015 healthcare agency questionnaire, for firms hoping to be featured in the Top 100 Agencies issue, is live. Click here to be considered.

Email Newsletters